Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mebendazole Regimens for Hookworm in Children and Adolescents in Ghana
NCT03261596Phase 4Withdrawn
- Sponsor
- PATH
- Start
- Sep 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mebendazole in hookworm infection (2 arms), sponsored by PATH. Primary endpoint: Cure Rate (CR) against hookworm at 20 days. Planned start Sep 2017; status: withdrawn.
02
Drugs
mebendazole
03
Conditions
hookworm infection
Beyond the preview
Go deeper on NCT03261596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03261596.